Literature DB >> 6380197

Clonazepam and vibration in restless legs syndrome.

P Montagna, L Sassoli de Bianchi, M Zucconi, F Cirignotta, E Lugaresi.   

Abstract

There have been no controlled therapeutic trials in Restless Legs Syndrome (RLS). In 6 patients with RLS, a randomized double-blind cross-over trial vs placebo showed a significant efficacy of clonazepam in improving subjective quality of sleep and leg dysaesthesia. Vibratory stimulation of the leg showed a less pronounced and non-significant effect. Clonazepam is a safe and effective drug for treatment of RLS; however its long-term efficacy needs confirmation.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6380197     DOI： 10.1111/j.1600-0404.1984.tb07826.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  24 in total

Review 1.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 2.  Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment.

Authors:  Paul Yeh; Arthur S Walters; John W Tsuang
Journal:  Sleep Breath       Date:  2011-10-26       Impact factor: 2.816

Review 3.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

Review 4.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

6.  Restless legs syndrome.

Authors:  C Bernick; L Z Stern
Journal:  West J Med       Date:  1986-08

7.  Controlled clinical, polysomnographic and psychometric studies on differences between sleep bruxers and controls and acute effects of clonazepam as compared with placebo.

Authors:  Alexander Saletu; Silvia Parapatics; Peter Anderer; Michael Matejka; Bernd Saletu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-15       Impact factor: 5.270

8.  Treatment options for sleep dysfunction in Parkinson's disease.

Authors:  Mary Ann Thenganatt; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

9.  Restless leg syndrome and rheumatoid arthritis.

Authors:  G Reynolds; D R Blake; H S Pall; A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-08

Review 10.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.